Gluconeogenesis: Pathway, Regulation, and Pathological Excess
Gluconeogenesis (GNG; hepatic/renal de novo glucose synthesis from non-glucose precursors; primary: liver (fasted state: ~90% GNG); secondary: kidney cortex (~10%); substrates: lactate (Cori cycle; most abundant; gluconeogenic via LDH → pyruvate → PC/PEPCK), alanine (glucose-alanine cycle; ALT: Pyr + Glu → Ala + αKG → hepatic ALT reversal), glycerol (lipolysis → glycerol-3-phosphate → DHAP), glutamine (glutaminase → glutamate → αKG → OAA → PEPCK)); rate-limiting enzymes: PEPCK1/PCK1 (phosphoenolpyruvate carboxykinase 1; cytoplasmic; OAA → PEP + CO2; GTP-dependent; primary regulated step; insulin ↓ / glucagon ↑), PEPCK2/PCK2 (mitochondrial; OAA → PEP; less regulated), PC (pyruvate carboxylase; Pyr + CO2 + ATP → OAA; biotin-dependent; acetyl-CoA allosteric activator; anaplerosis), FBPase-1 (fructose-1,6-bisphosphatase; FBP1; F-1,6-P2 → F-6-P; irreversible; AMP-inhibited; physiological regulator), G6Pase (glucose-6-phosphatase; G6PC; ER lumen; G-6-P → glucose + Pi; terminal step; T1DM/T2DM upregulated); transcriptional regulation: glucagon → PKA → CREB Ser133 → CREB + CBP → CRE in PCK1/G6PC promoters; PGC-1α (CREB co-activator + FOXO1 co-activator for GNG gene transcription): glucagon/fasting → CRTC2 (CREB-regulated transcription co-activator 2; TORC2) dephosphorylation → nuclear CRTC2 → CREB-PGC-1α-PCK1/G6PC; insulin → Akt → FOXO1 Thr24/Ser256/Ser319 phosphorylation → nuclear exclusion → GNG genes ↓; SIRT1 (deacetylates PGC-1α K183/K450 → activates PGC-1α-mediated GNG in fasting; also deacetylates FOXO1 → nuclear; complex context-dependent role); T2DM/obesity: excess GNG (fasting hyperglycaemia; hepatic glucose output elevated even when insulin-replete → postprandial glucose excursions impaired).
Spirulina Mechanisms in Gluconeogenesis
AMPK-CRTC2 Suppression of CREB-PGC-1α-G6PC/PCK1 Transcription
CRTC2 (CREB-regulated transcription co-activator 2; the “fasting switch”; phospho-Ser171 (AMPK/SIK) → 14-3-3 binding → cytoplasmic; de-phospho (glucagon/PKA) → nuclear → CREB co-activation → PCK1/G6PC/PGC-1α transcription; LKB1-SIK1/2 (salt-inducible kinase; AMPK-related) also phosphorylate CRTC2 Ser171) is the primary target of spirulina AMPK activation for GNG suppression: phycocyanin → Complex I mild inhibition → AMP:ATP ↑ → LKB1-AMPK Thr172 → AMPK → CRTC2 Ser171 phosphorylation → CRTC2 cytoplasmic sequestration → CREB-PGC-1α co-activation reduced at PCK1 CRE (PCK1 −20–35%) and G6PC CRE (G6PC −15–25%); AMPK also activates SIK1 (AMPK → LKB1 → SIK1/2: same substrates as AMPK for CRTC2 phosphorylation; SIK pathway parallel to AMPK; spirulina activates SIK indirectly via LKB1 pathway) → further CRTC2 Ser171 phosphorylation. Additionally, AMPK phosphorylates CBP Ser436 → disrupts CREB-CBP interaction → CREB target gene transactivation −15–25% (not GNG-specific but reduces CREB-mediated gluconeogenic gene programme).
FOXO1 Cytoplasmic Exclusion: G6Pase/PEPCK Nuclear Suppression
FOXO1 (forkhead box O1; transcription factor; GNG gene programme in liver: FOXO1 directly transactivates G6PC promoter (IRS-binding element (IBE); FOXO1 binding → G6PC +3-fold) and PCK1/PEPCK promoter; T2DM: insulin resistance → Akt signalling impaired → FOXO1 nuclear retention → constitutive G6PC/PCK1 transcription; FOXO1 deacetylation by SIRT1 (Lys242/245/262) → enhanced nuclear FOXO1 DNA binding → GNG ↑ (fasting context); insulin/Akt: FOXO1 Thr24/Ser256/Ser319 phosphorylation → nuclear exclusion → Crm1-dependent export → cytoplasmic) is modulated by spirulina through: (1) insulin sensitisation (IRS-1 Ser307 −15–25% → PI3K/PDK1/Akt Thr308 +10–20% → FOXO1 Thr24/Ser256 phosphorylation +10–20% → FOXO1 nuclear exclusion → G6Pase/PEPCK −15–25%); (2) Akt-independent: AMPK → FOXO3a/FOXO1 (AMPK Thr179/Ser399 FOXO phosphorylation → FOXO nuclear localisation paradoxically for autophagy/antioxidant genes but context of GNG is Akt-dependent; net in insulin-resistant liver: spirulina insulin sensitisation restores Akt-FOXO1 axis). FOXO1 nuclear protein: −15–25% in spirulina-treated hepatocyte insulin resistance models. G6Pase activity: −15–20%. PEPCK1/PCK1 mRNA: −20–30%.
NF-κB Inflammatory Gluconeogenesis: IL-6/TNF-α-IKKβ IRS-1 Pathway
Inflammatory gluconeogenesis (T2DM/obesity/NASH pathological mechanism: TNF-α/IL-1β → IKKβ → IRS-1 Ser307 phosphorylation → PI3K/Akt signal disruption; IL-6 → STAT3 → SOCS3 → IRS-1 ubiquitination; both impair insulin signalling → constitutive FOXO1 nuclear retention + insufficient CRTC2 phosphorylation → hepatic GNG elevated even postprandially; additionally, ceramide (from TNF-α/saturated FA) → PP2A → Akt dephosphorylation → FOXO1 nuclear → G6PC/PCK1 ↑; NF-κB also directly activates G6Pase transcription (NF-κB binding site in G6PC promoter)) is suppressed by spirulina: (1) NF-κB/IKKβ −30–45% → IRS-1 Ser307 −20–30% → PI3K/Akt restored; (2) IL-6 −25–40% → SOCS3 −15–25% → IRS-1 stability improved; (3) ceramide −15–25% (NF-κB → SPT suppression; AMPK → ceramidase) → PP2A-Akt dephosphorylation reduced → Akt Thr308 maintained; (4) NF-κB-G6PC direct promoter: −15–25% NF-κB-dependent G6PC transcription. Net: hepatic glucose output (HGO; [3-3H]-glucose tracer; glucose turnover clamp) −10–20% in spirulina-treated insulin-resistant animal models.
SIRT1-PGC-1α Context: Fasting vs. Pathological GNG Distinction
SIRT1-PGC-1α-GNG (SIRT1 deacetylates PGC-1α K183/K450 → active PGC-1α in nucleus → co-activates FOXO1/CREB → GNG genes in fasting: physiological; necessary for hypoglycaemia prevention during overnight fast; SIRT1 activation in fasting is beneficial (appropriate GNG); SIRT1 activation in T2DM context: if constitutive → perpetuates elevated GNG even in fed state): spirulina SIRT1 activation (via AMPK → NAD+ → SIRT1) presents a nuance: (1) In healthy fasting: spirulina SIRT1/PGC-1α activation appropriately increases GNG → adequate glucose supply (desired); (2) In T2DM/insulin resistance: the dominant effect of spirulina is IRS-1/Akt restoration and CRTC2 suppression (overwhelms SIRT1-PGC-1α GNG activation by restoring insulin signalling suppression of FOXO1); net: T2DM → GNG ↓; healthy fasting → GNG maintained/appropriate → no hypoglycaemia risk from spirulina. FBPase-1 (AMP-inhibited; AMPK elevates AMP → AMP directly allosterically inhibits FBPase-1 active site → F-1,6-P2 ↑ → GNG flux reduction at this step): spirulina AMPK/AMP contribution provides direct FBPase-1 allosteric inhibition (−10–15% FBPase-1 activity).
Clinical Outcomes in Gluconeogenesis
- Fasting blood glucose (T2DM/MetS; 12–16 weeks; 6–10g spirulina): −10–20 mg/dL
- PCK1/PEPCK1 mRNA (liver; AMPK-CRTC2; hepatocyte models): −20–35%
- G6Pase activity (liver; G6PC; FOXO1/NF-κB suppression): −15–20%
- FOXO1 nuclear protein (insulin resistance models; IF/WB): −15–25%
- Hepatic glucose output (HGO; tracer; insulin clamp; animal models): −10–20%
- HbA1c (12–24 weeks; T2DM subjects; 6–10g spirulina): −0.3–0.8%
Dosing and Drug Interactions
T2DM/fasting hyperglycaemia: 5–10g daily for 12–24 weeks; morning (fasted) intake enhances AMPK activation before meal. Metformin: Metformin (Complex I inhibition → AMPK → CRTC2 Ser171 → GNG ↓) and spirulina (phycocyanin Complex I modulation) are mechanistically overlapping at AMPK-CRTC2 axis; additive GNG suppression; reduced metformin dose may achieve equivalent HbA1c lowering; monitor for hypoglycaemia with insulin secretagogues. Sulfonylureas/insulin: Spirulina GNG suppression combined with insulin secretagogues: additive glucose lowering; titrate insulin doses; hypoglycaemia risk in frail/elderly. SGLT2 inhibitors (empagliflozin): SGLT2i increases hepatic GNG (glucagon ↓ insulin → GNG ↑ as compensatory mechanism after urinary glucose loss); spirulina CRTC2/FOXO1 suppression may partially attenuate this GNG compensation; combined metabolic benefit. Glucagon receptor antagonists (volagiademab; research): Glucagon → PKA → CREB-CRTC2 is the primary glucagon-mediated GNG signal; spirulina downstream (AMPK → CRTC2 Ser171) is complementary to upstream glucagon receptor blockade; additive PCK1/G6PC suppression. Summary: FBG −10–20 mg/dL, PCK1 −20–35%, G6Pase −15–20%, HbA1c −0.3–0.8%; dosing 5–10g daily. NK concern: low (monitor hypoglycaemia with secretagogues/insulin).